Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (6)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shretta, R
Right arrow Articles by Snow, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shretta, R
Right arrow Articles by Snow, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Health Policy and Planning; 16(2): 161-170
© Oxford University Press 2001

A political analysis of corporate drug donations: the example of Malarone® in Kenya

R Shretta1,2, G Walt2, R Brugha2 and RW Snow1,3

1 Kenya Medical Research Institute (KEMRI)/Wellcome Trust, Collaborative Programme, Nairobi, Kenya,
2 Health Policy Unit, London School of Hygiene and Tropical Medicine, London, UK and
3 Centre for Tropical Medicine, Nuffield Department for Clinical Medicine, University of Oxford, John Radcliffe Hospital, Oxford, UK

This paper describes the introduction of the Malarone® Donation Programme in Kenya. Using a policy analysis approach it illustrates the political nature of donation programmes and how they are affected by a large and varied group of national, regional and international stakeholders, with different levels of influence and experience. The paper shows that interaction between these different groups may affect the development and implementation of the donation programme. It ends by raising some more general questions about public/private partnerships and corporate donation programmes, and their potential impact on national drug policies.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Trop Med HygHome page
W. M. WATKINS, C. H. SIBLEY, and I. M. HASTINGS
THE SEARCH FOR EFFECTIVE AND SUSTAINABLE TREATMENTS FOR PLASMODIUM FALCIPARUM MALARIA IN AFRICA: A MODEL OF THE SELECTION OF RESISTANCE BY ANTIFOLATE DRUGS AND THEIR COMBINATIONS
Am J Trop Med Hyg, February 1, 2005; 72(2): 163 - 173.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
R. Brugha and G. Walt
A global health fund: a leap of faith?
BMJ, July 21, 2001; 323(7305): 152 - 154.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.